SIONHealthcare · BiotechnologyThe 12 Wall Street analysts covering Sionna Therapeutics, Inc. hold a median 12-month price target of $6 — -12.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 25 of 100 as at 15 Sept 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Sionna Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (77): Reported profit is backed by cash, and the company is not expanding recklessly.
Momentum (6): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on SION, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −12.8% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 11 Aug 2026 | Guggenheim | Downgrade | Neutral | — |
| 11 Aug 2026 | Wedbush | Downgrade | Neutral | $53 → $5.00 |
| 10 Aug 2026 | BTIG | Downgrade | Neutral | — |
| 7 Aug 2026 | Guggenheim | Maintains | Buy | $50 → $60 |
| 26 May 2026 | Citizens | Reiterates | Market Outperform | $63 |
| 26 May 2026 | Citizens | Reiterates | Market Outperform | — |
| 20 May 2026 | Freedom Broker | Downgrade | Hold | — |
| 20 May 2026 | Freedom Broker | Downgrade | Hold | $38 |
| 18 May 2026 | Stifel | Maintains | Buy | — |
| 13 May 2026 | BTIG | Reiterates | Buy | — |
| 5 May 2026 | Wedbush | Initiates | Outperform | — |
| 28 Apr 2026 | Jones Trading | Maintains | Buy | — |
| 27 Apr 2026 | BTIG | Reiterates | Buy | — |
| 3 Mar 2026 | Guggenheim | Maintains | Buy | — |
| 2 Mar 2026 | BTIG | Reiterates | Buy | — |
| 24 Feb 2026 | Citizens | Initiates | Market Outperform | — |
| 14 Jan 2026 | BTIG | Reiterates | Buy | — |
| 7 Jan 2026 | BTIG | Maintains | Buy | — |
| 23 Dec 2025 | LifeSci Capital | Initiates | Outperform | — |
| 1 Dec 2025 | RBC Capital | Downgrade | Underperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SION appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 15 Sept 2026, Sionna Therapeutics, Inc. returned −69.2% against +15.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 89% of US stocks
Cheaper than 59% of US stocks
Cheaper than 70% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 26% of US stocks
Higher than 18% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Sionna Therapeutics, Inc. has a market value of $372.9M and an enterprise value of $170.5M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$97.4M.
Diluted earnings per share, trailing twelve months: $−2.18.
Free cash flow in the twelve months to 30 June 2026: −$76.2M.
Trailing P/E: −4.4×; forward P/E: −3.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Sionna Therapeutics, Inc. employs 59 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Sionna Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Sionna Therapeutics plans to cut its workforce by 46% after its cystic fibrosis candidate SION-719 failed a key study. The company is shifting focus to its other programs, SION-451 and SION-2222.
Why it matters — SION watchers would care because the lead program's failure and a nearly half-sized workforce reduction represent a major strategic setback for the company.
Sionna Therapeutics discussed a post-hoc analysis of its PreciSION cystic fibrosis (CF) trial and the advancement of its dual combination program in a company discussion (transcript) covered by Seeking Alpha.
Why it matters — A SION watcher would care because the post-hoc trial analysis and advancement of the dual combination program signal ongoing progress in the company's cystic fibrosis development pipeline.
Sionna Therapeutics announced plans to advance a dual combination of SION-451 and SION-2222 into a Phase 2a proof-of-concept trial. Post hoc analyses of the SION-719 PreciSION CF subset showed a mean placebo-adjusted sweat chloride reduction of up to -8.6 mmol/L, consistent with NBD1 biological activity.
Why it matters — A Sionna watcher would care because the company is advancing a promising next-stage combination therapy based on data indicating NBD1 biological activity in cystic fibrosis treatment.
Shareholder rights law firm Robbins LLP announced it is investigating Sionna Therapeutics to determine whether certain of the company's officers and directors violated securities laws and breached fiduciary duties to shareholders.
Why it matters — A securities investigation by a shareholder law firm into potential violations by Sionna's leadership raises governance and legal risk concerns for investors watching the company.
The 12 Wall Street analysts covering Sionna Therapeutics, Inc. have a median 12-month price target of $6, with estimates ranging from $5 to $63. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 12 analysts covering Sionna Therapeutics, Inc., 2 rate it a Buy, 10 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Sionna Therapeutics, Inc. 25 out of 100 across roughly 4,600 US stocks as at 15 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 15 Sept 2026, Sionna Therapeutics, Inc. ranks 25 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (77 of 100).
No one can know that. What the data says: the median 12-month target from 12 analysts implies -12.8% from the last close, and Ticker Nerd's factor model ranks Sionna Therapeutics, Inc. 25 out of 100 as at 15 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Sionna Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SION are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $63 over the next 12 months.
Sionna Therapeutics, Inc. returned -69.2% over the 12 months to 15 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Sionna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for cystic fibrosis.
The most recent item we track (Zacks Investment Research, 16 Sept 2026): "SION to Cut Workforce by Nearly Half After CF Study Failure, Stock Down". Sionna Therapeutics plans to cut its workforce by 46% after its cystic fibrosis candidate SION-719 failed a key study. The company is shifting focus to its other programs, SION-451 and SION-2222.
Sionna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for cystic fibrosis. Its current portfolio centers on small-molecule therapies designed to improve the function of the cystic fibrosis transmembrane conductance regulator, or CFTR, protein, with programs that include CFTR correctors, potentiators, and NBD1 stabilizers. The company’s work is aimed at addressing the underlying protein defects associated with cystic fibrosis, including approaches intended to work in combination with complementary modulators. Sionna Therapeutics operates as a research and development-driven organization with no commercial product portfolio disclosed in the available information. It is headquartered in Waltham, Massachusetts, and serves the biotechnology and pharmaceutical research markets through its focus on rare disease drug development.
CEO Mr. Michael Cloonan M.B.A. · 59 employees · United States · https://www.sionnatx.com
